XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xilio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.07 (−19.94%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Xilio Therapeutics, Inc. grew revenue 327.3% to $64.09M over the twelve months to Jun 30, 2026. Free cash flow was -$61.27M.
Revenue
$64.09M
+327.3% vs. a year earlier
Operating income
-$31.37M
TTM Q2 2026
Free cash flow
-$61.27M
TTM Q2 2026
EPS, diluted
-$4.19
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $161.64M
- P/E ratio
- –
- Price to sales
- 2.52
- Price to book
- 2.24
- Dividend yield
- –
- Free cash flow yield
- -37.90%
Fundamentals
- Revenue
- $64.09M
- Net income
- -$21.83M
- EPS, diluted
- -$4.19
- Free cash flow
- -$61.27M
- Book value per share
- $3.72
- Diluted shares
- 19M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$64.09M+327.3% YoY
Operating income
-$31.37M
Net income
-$21.83M
EPS, diluted
–
Free cash flow
-$61.27M
Reported periodTrailing twelve months